Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: Comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 6, 2004, Pages 1062-1066

  Odenholt, Inga ^a,b   Cars, Otto ^a   Löwdin, Elisabeth ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibiotics; In vitro kinetic models; PK PD; S. pneumoniae

Indexed keywords

AMOXICILLIN; CLAVULANIC ACID;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; ERADICATION THERAPY; IN VITRO STUDY; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; SIMULATION; STANDARD; STRAIN DIFFERENCE; STREPTOCOCCUS PNEUMONIAE;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CLAVULANIC ACID; COLONY COUNT, MICROBIAL; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PHARMACOKINETICS; STREPTOCOCCUS PNEUMONIAE;

EID: 12344281832     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh484     Document Type: Article

References (26)

1. Todd, P. A. & Benfield, P. (1990). Amoxicillin/clavulanic acid: an update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 39, 264-307.
2. White, A. R., Kaye, C., Poupard, J. et al. (2004). Augmentin® (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. Journal of Antimicrobial Chemotherapy 53, Suppl. S1, 3-20.
3. File, T. M., Jr, Jacobs, M. R., Poole, M. D. et al. (2002). Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate. International Journal of Antimicrobial Agents 20, 235-47.
4. Petitpretz, P., Chidiac, C., Soriano, F. et al. (2002). The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults. International Journal of Antimicrobial Agents 20, 119-29.
5. Garau, J., Twynholm, M., Garcia-Mendez, E. et al. (2003). Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. Journal of Antimicrobial Chemotherapy 52, 826-36.
6. Vogelman, B., Gudmundsson, S., Turnidge, J. et al. (1988). Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. Journal of Infectious Diseases 158, 831-47.
7. Craig, W. A. & Andes, D. (1996). Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatric Infectious Disease Journal 15, 255-9.
8. Cars, O. (1997). Efficacy of β-lactam antibiotics: integration of pharmacokinetics and pharmacodynamics. Diagnostic Microbiology and Infectious Disease 27, 29-33.
9. Drusano, G. I. & Craig, W. A. (1997). Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. Journal of Chemotherapy 9, Suppl. 3, 38-44.
10. Andes, D. & Craig, W. A. (1998). In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrobial Agents and Chemotherapy 42, 2375-9.
11. Craig, W. A. (1998). Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases 26, 1-12.
12. Dagan, R., Klugman, K. P., Craig, W. A. et al. (2001). Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. Journal of Antimicrobial Chemotherapy 47, 129-40.
13. Gustafsson, I., Löwdin, E., Odenholt, I. et al. (2001). Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model. Antimicrobial Agents and Chemotherapy 45, 2436-40.
14. National Committee for Clinical Laboratory Standards. (2003). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard M7-A6. NCCLS, Wayne, PA, USA.
15. Cars, O., Henning, C. & Holm, S. E. (1981). Penetration of ampicillin and dicloxacillin into tissue cage fluid in rabbits: relation to serum and tissue protein binding. Scandinavian Journal of Infectious Diseases 13, 69-74.
16. Löwdin, E., Odenholt, I., Bengtsson, S. et al. (1996). Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model. Antimicrobial Agents and Chemotherapy 40, 2478-82.
17. Löwdin, E., Odenholt, I. & Cars, O. (1998). In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrobial Agents and Chemotherapy 42, 2739-44.
18. Löwdin, E., Odenholt, I. & Cars, O. (2002). Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model; a comparison of different dosage regimens including a pharmacokinetically enhanced formulation. Clinical Microbiology and Infection 8, 646-53.
19. Kaye, C., Allen, A., Perry, S. et al. (2001). The clinical pharmacokinetics of a new pharmacokinetically enhanced amoxicillin/clavulanic acid formulation. Clinical Therapeutics 23, 578-84.
20. Ball, P., Baquero, F., Cars, O. et al. (2002). Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. Journal of Antimicrobial Chemotherapy 49, 31-40.
21. Dagan, R. (2003). Achieving bacterial eradication using pharmacokinetic/pharmacodynamic principles. International Journal of Infectious Diseases 7, 21-6.
22. Jacobs, M. R., Felmingham, D., Appelbaum, P. C. et al. (2003). The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. Journal of Antimicrobial Chemotherapy 52, 229-46.
23. Aguilar, L., Giménez, M. J., Garcia-Rey, C. et al. (2002). New strategies to overcome antimicrobial resistance in Streptococcus pneumoniae with β-lactam antibiotics. Journal of Antimicrobial Chemotherapy 50, Suppl. S2, 93-100.
24. Jacobs, M. R. (2003). How can we predict bacterial eradication? International Journal of Infectious Diseases 7, 13-20.
25. Andes, D. & Craig, W. A. (2002). Animal model pharmacokinetics and pharmacodynamics: a critical review. International Journal of Antimicrobial Agents 19, 261-8.
26. Woodnutt, G. & Berry, V. (1999). Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 43, 35-40.